uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Selection and characterization of HER2/neu-binding affibody ligands
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Show others and affiliations
2004 (English)In: Protein Engineering Design & Selection, ISSN 1741-0126, Vol. 17, no 5, 455-462 p.Article in journal (Refereed) Published
Abstract [en]

Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphylococcal protein A-derived Z domain. The predominant variants from the phage selection were produced in Escherichia coli, purified by affinity chromatography, and characterized by biosensor analyses. Two affibody variants were shown to selectively bind to the extracellular domain of HER2/neu (HER2-ECD), but not to control proteins. One of the variants, denoted His6-ZHER2/neu:4, was demonstrated to bind with nanomolar affinity (approximately 50 nM) to the HER2-ECD molecule at a different site than the monoclonal antibody trastuzumab. Furthermore, radiolabeled His6-ZHER2/neu:4 affibody showed specific binding to native HER2/neu, overexpressed on the SKBR-3 tumor cell line. Such affibody ligands might be considered in tumor targeting applications for radionuclide diagnostics and therapy of adenocarcinomas such as breast and ovarian cancers.

Place, publisher, year, edition, pages
2004. Vol. 17, no 5, 455-462 p.
Keyword [en]
Amino Acid Sequence, Antibodies; Monoclonal/pharmacology, Antineoplastic Agents/pharmacology, Biosensing Techniques, Humans, Iodine Radioisotopes, Ligands, Molecular Sequence Data, Protein Structure; Secondary, Receptor; erbB-2/antagonists & inhibitors/genetics/*metabolism, Research Support; Non-U.S. Gov't, Time Factors
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-94183DOI: 10.1093/protein/gzh053PubMedID: 15208403OAI: oai:DiVA.org:uu-94183DiVA: diva2:167948
Available from: 2006-03-30 Created: 2006-03-30 Last updated: 2014-03-05Bibliographically approved
In thesis
1. Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting: Preclinical Studies
Open this publication in new window or tab >>Radiolabeled HER-2 Binding Affibody Molecules for Tumor Targeting: Preclinical Studies
2006 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Conventional cancer treatment based on radiotherapy or chemotherapy affects all dividing cells. By directing the therapy specifically to the tumor cells, normal cells can be spared. Tumor targeting molecules carrying a cytotoxic moiety is then an attractive approach.

In this thesis, an affibody molecule with high affinity for the protein HER-2, that is strongly associated with aggressive forms of breast cancer, was selected. After radiolabeling with 125I, the affibody molecule, in monovalent and bivalent form, was tested in vitro in HER-2 overexpressing tumor cells and in transplanted tumors in mice.

It was shown that the HER-2 targeting affibody molecule bound its target in a specific manner, both in vitro and in vivo. The small size of the affibody molecule resulted in fast clearance through the kidneys. An impressive tumor-to-blood ratio of 10 eight hours post injection was achieved and the tumors could easily be visualized in a gamma camera.

The biologic effects of the bivalent affibody molecule and a monovalent affinity maturated version was measured and compared with the effects of the monoclonal antibody trastuzumab. It was found that although all molecules target the same protein, the effects differed greatly.

The affibody molecule was also labeled with the alpha-emitting radionuclide 211At. Specific decrease in survival was seen in HER-2 overexpressing cells receiving the 211At labeled affibody molecule. The sensitivity to the treatment differed between cell lines, probably as a result of differences between the cell lines in internalization and nuclear size. The 211At labeled affibody molecules were also tested in vivo, where stability of the 211At label was a problem. To circumvent this problem, more stable conjugation chemistry was tested, as well as strategies to prevent uptake of released 211At by normal organs.

This thesis describes the selection and optimization of affibody molecules for medical use for the first time.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2006. 63 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 127
Biomedicine, HER-2, affibody, 211At, tumor targeting, targeted radiotherapy, molecular imaging, Biomedicin
National Category
Microbiology in the medical area
urn:nbn:se:uu:diva-6678 (URN)91-554-6503-X (ISBN)
Public defence
2006-04-22, Rudbecksalen, Rudbecklaboratoriet, Dag Hammarskölds väg 20, UPPSALA, 09:15
Available from: 2006-03-30 Created: 2006-03-30Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Tolmachev, VladimirCarlsson, Jörgen
By organisation
Biomedical Radiation SciencesDepartment of Oncology, Radiology and Clinical Immunology
In the same journal
Protein Engineering Design & Selection
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 335 hits
ReferencesLink to record
Permanent link

Direct link